Table 1.
Pattern of use of SSRIs and average DDD in 1995–1999 and 2000–2004 for pregnancies exposed to an SSRI in period from 3 months before conception until delivery
| Total | 1995–1999 | 2000–2004 | |||||
|---|---|---|---|---|---|---|---|
| n = 310 | (100%) | n = 90 | (100%) | n = 220 | <(100%) | P | |
| Use before pregnancy | 274 | 88.4 | 81 | 90.0 | 193 | 87.7 | |
| Use discontinued before theoretical conception date | 105 | 38.3 | 39 | 48.1 | 66 | 34.2 | 0.03 |
| Use continued in pregnancy | 169 | 61.7 | 42 | 51.9 | 127 | 65.8 | |
| Start use in pregnancy | 36 | 11.6 | 9 | 10.0 | 27 | 12.3 | |
| Average DDD prescribed | |||||||
| ≤1 DDD | 229 | 73.9 | 69 | 76.7 | 160 | 72.7 | 0.474 |
| >1 DDD | 81 | 26.1 | 21 | 23.3 | 60 | 27.3 | |
SSRI, Selective serotonin reuptake inhibitor; DDD, defined daily dose. SSRIs include paroxetine (ATC N06AB05; DDD 20 mg), fluoxetine (ATC N06AB03; DDD 20 mg), fluvoxamine (ATC N06AB08; DDD 100 mg), citalopram (ATC N06AB04; DDD 20 mg) and sertraline (ATC N06AB06; DDD 50 mg).